June 16, 2020
Kyowa Kirin said on June 15 that it has launched its cancer drug Poteligeo (mogamulizumab) in Germany for the treatment of two subtypes of cutaneous T-cell lymphoma (CTCL) - mycosis fungoides (MF) and Sézary syndrome (SS). Poteligeo, an anti-CCR4 monoclonal...read more